Verification evidence is still being completed.
PDF / print export
Indivumed Therapeutics GmbH
Hamburg, Germany
- Verified lead
- Hartmut Juhl
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Founder and Chief Executive Officer
- 2026 technical specialization
- AI-Driven Precision Oncology, Multi-Omics Target Discovery, and Global Clinical Sample Networks
- Review cycle
- 24 April 2026
- Full address
- Falkenried 88, Building D, 20251 Hamburg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Indivumed Therapeutics official About Us page.
- Editorial note
- Hamburg AI-driven precision-oncology therapeutics company built on the IndivuType multi-omics database, led by founder-CEO Hartmut Juhl, with a global clinical sample network accessed via the Crown Bioscience partnership.
AI-Driven Precision Oncology, Multi-Omics Target Discovery, and Global Clinical Sample Networks
Public founder and CEO disclosure, Documented 2023 Crown Bioscience acquisition of services arm, Published evolution into Indivumed Therapeutics
Hamburg AI-driven precision-oncology therapeutics company built on the IndivuType multi-omics database, led by founder-CEO Hartmut Juhl, with a global clinical sample network accessed via the Crown Bioscience partnership.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Hamburg, Germany
Indivumed Therapeutics GmbH
AI-Driven Precision Oncology, Multi-Omics Target Discovery, and Global Clinical Sample Networks · AI-driven target and compound discovery
Hamburg AI-driven precision-oncology therapeutics company built on the IndivuType multi-omics database, led by founder-CEO Hartmut Juhl, with a global clinical sample network accessed via the Crown Bioscience…
- Lead
- Hartmut Juhl (verified ↗)
- Address
- Falkenried 88, Building D, 20251 Hamburg, Germany (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- AI-driven target and compound discovery
- Capabilities
- IndivuType Multi-Omics Cancer Database · AI-Driven Target Discovery · Global Clinical Sample Network
- Founded
- 2002
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Hartmut Juhl
Founder and Chief Executive Officer
Full addressFalkenried 88, Building D, 20251 Hamburg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Indivumed About Us page listing Falkenried 88 as the Hamburg headquarters.
Open sourceAI-driven target and compound discovery
Hamburg, Germany. AI-Driven Precision Oncology, Multi-Omics Target Discovery, and Global Clinical Sample Networks. Review completed on 24 Apr 2026.
BfArM and EMA for any future clinical development
Public founder and CEO disclosure, Documented 2023 Crown Bioscience acquisition of services arm, Published evolution into Indivumed Therapeutics
AI-Driven Precision Oncology, Multi-Omics Target Discovery, and Global Clinical Sample Networks
Hamburg AI-driven precision-oncology therapeutics company built on the IndivuType multi-omics database, led by founder-CEO Hartmut Juhl, with a global clinical sample network accessed via the Crown Bioscience partnership.
Editorial note
Indivumed Therapeutics is the therapeutics-focused remainder of the Indivumed group after the 2023 Crown Bioscience acquisition of the services and biobank arm, combining an IndivuType multi-omics database with AI-driven target discovery.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
IndivuType Multi-Omics Cancer Database
AI-Driven Target Discovery
Global Clinical Sample Network
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Multi-omics informatics platform
AI target-discovery workflow
Partner access to clinical sample network and biobank via Crown Bioscience
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Indivumed Therapeutics GmbH located?
- Indivumed Therapeutics GmbH operates from Falkenried 88, Building D, 20251 Hamburg, Germany, Hamburg, Germany.
- Who runs Indivumed Therapeutics GmbH?
- Indivumed Therapeutics GmbH is led by Hartmut Juhl, Founder and Chief Executive Officer. Verified 24 Apr 2026.
- What does Indivumed Therapeutics GmbH do?
- Hamburg AI-driven precision-oncology therapeutics company built on the IndivuType multi-omics database, led by founder-CEO Hartmut Juhl, with a global clinical sample network accessed via the Crown Bioscience… Core capabilities: IndivuType Multi-Omics Cancer Database, AI-Driven Target Discovery, Global Clinical Sample Network.
Editorial context
Related technical briefs
Briefs that name Hamburg as a covered market or city.